Infallible Pharma aims to boost its presence in Critical Care Segment in India and Overseas

Infallible Pharma has announced its plans to boost its presence in critical care segment in India and overseas.

Mr. Hari Om, Chairman, Infallible Pharma Private Ltd. said, “While we have already achieved the number one position in the anticoagulant segment, we are also one of the largest providers of the medicines used in dialysis care in India. During the pandemic when suddenly there was a dearth of critical care medicines due to the unexpected stoppage of imports, Infallible Pharma played a significant role in attending all the emergency calls and supplying the required medicines without any disruptions through its stocks. Coming to our expansion plans, our 90% of the business comes from West and South India and currently we are expanding heavily in North India while giving utmost attention to our brand value creation at the same time.”

The company said in a statement, “Apart from India, Infallible Pharma is also expanding its wings in South American and Latin American regions. It exports its antibiotics to the US and Russia. Present in almost all the districts and major cities in India, Infallible Pharma has its major market is south, north-east India and Uttar Pradesh. With its manufacturing facilities in Baddi and Solan in Himachal Pradesh, Infallible Pharma produces primarily injectable medicines apart from oral capsules and tablets. One of the leading manufacturers of life-saving drugs, Infallible Pharma’s products include antibiotics, anesthetical and nephrology segments and its customer base includes Glan Pharma, Aishwarya Healthcare, Cipla, Shri Anand Pharmaceuticals, Apollo Hospitals and Apollo Pharmacy. The company is also all set to make its entry into Hepatitis segment.”

+ posts

Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of  economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.

What's your take on this post ? Comment: